Actively Recruiting
Phase 1 Study of RS-C1001 Tablets to Evaluate Safety, Tolerability, and Effects in Healthy Chinese Adults Aged 18 to 45
Led by Peking University First Hospital · Updated on 2024-11-01
72
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of food on RS-C1001 tablets in healthy Chinese adults aged 18 to 45 years. This Phase I, first-in-human, randomized, double-blind, placebo-controlled study aims to understand how RS-C1001 behaves in the body and its safety profile. The study is divided into two parts, including single and multiple dose assessments.
CONDITIONS
Brief Title
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects
Research Team
P
professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
